Zevra Therapeutics Inc ZVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
-
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C — 2nd Update
-
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C — Update
-
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
-
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C
-
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
-
Zevra Therapeutics to Participate at Upcoming Investor Conferences
-
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
Trading Information
- Previous Close Price
- $7.18
- Day Range
- $7.07–7.41
- 52-Week Range
- $3.89–8.95
- Bid/Ask
- $7.08 / $7.27
- Market Cap
- $378.85 Mil
- Volume/Avg
- 718,964 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 69
- Website
- https://www.zevra.com
Comparables
Valuation
|
Metric
|
ZVRA
|
TERN
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 9.31 | 2.66 | 1.77 |
Price/Sales | 11.79 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ZVRA
TERN
PLRX
Financial Strength
|
Metric
|
ZVRA
|
TERN
|
PLRX
|
|---|---|---|---|
Quick Ratio | 1.91 | 20.57 | 14.21 |
Current Ratio | 2.00 | 21.02 | 14.47 |
Interest Coverage | −16.32 | — | −106.49 |
Quick Ratio
ZVRA
TERN
PLRX
Profitability
|
Metric
|
ZVRA
|
TERN
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −47.15% | −28.87% | −27.65% |
Return on Equity (Normalized) | −120.36% | −30.36% | −31.11% |
Return on Invested Capital (Normalized) | −68.56% | −34.37% | −33.69% |
Return on Assets
ZVRA
TERN
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bstnkgyxrn | Nygw | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rtfqngnmw | Lhhrhg | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qrdvmzyq | Yjypj | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ghmkckxk | Bfcpzm | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Hmjbxnw | Fjh | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Wnmbfxys | Dbb | $29.2 Bil | |||
| Moderna Inc
MRNA
| Flnlvfmc | Rnrp | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Gbxszhdvz | Gkwyv | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Txxqpyxw | Gqtcnv | $13.2 Bil | |||
| Incyte Corp
INCY
| Xsxttnjqh | Ktxqm | $13.0 Bil |
United States